Skip Navigation



American Journal of Epidemiology Advance Access published online on March 21, 2008
American Journal of Epidemiology, doi:10.1093/aje/kwn051
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
167/9/1140    most recent
kwn051v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lennon, D.
Right arrow Articles by Crengle, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lennon, D.
Right arrow Articles by Crengle, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology © The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.

Letter to the Editor

RE: "A PROSPECTIVE STUDY OF THE EFFECTIVENESS OF THE NEW ZEALAND MENINGOCOCCAL B VACCINE"

Diana Lennon1, Joanna Stewart2 and Sue Crengle3

1 Department of Community Paediatrics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand
2 Department of Biomedical Statistics, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New Zealand
3 Department of Maori and Pacific Health, School of Medical Sciences, The University of Auckland, Auckland 1142, New Zealand

(e-mail: d.lennon@auckland.ac.nz)

The first 10% of the full text of this article appears below.

Although Kelly et al. (1) demonstrate the effectiveness of the outer-membrane-vesicle, strain-specific, meningococcal vaccine known as "MeNZB" in the overall New Zealand population with reported vaccine effectiveness of 73 percent (95 percent confidence interval: 52, 85), this may not reflect the true picture.

First, there is an indication of the poor fit of the model (1, figure 1), where the model's . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
C Jackson, D R Lennon, V T K Sotutu, J Yan, J M Stewart, S Reid, S Crengle, P Oster, E Ypma, I Aaberge, et al.
Phase II meningococcal B vesicle vaccine trial in New Zealand infants
Arch. Dis. Child., October 1, 2009; 94(10): 745 - 751.
[Abstract] [Full Text] [PDF]